Jun 02, 2020
Bergenbio Confirms First Covid-19 Patient Dosed With Bemcentinib in Accord Trial
May 07, 2020
Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates
May 05, 2020
BerGenBio Raises Nok500m (EUR45.4m) via an Over Subscribed Private Placement
Apr 28, 2020
BerGenBio's Bemcentinib Selected to Be Fast-tracked As Potential Treatment for COVID-19 Through New National UK Government Clinical Trial Initiative
Jan 15, 2020
BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda® in NSCLC Patients Progressing on Immune Checkpoint Inhibitors
Dec 09, 2019
BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019
Dec 03, 2019
Piramal Pharma Solutions Announces Collaboration With BerGenBio on the Development of FDA Fast Track Designated Leukemia Treatment
Nov 19, 2019
BerGenBio ASA: Results for the Third Quarter 2019
Nov 08, 2019
BerGenBio Presents Updated Phase 2 NSCLC Clinical and Translational Data for Bemcentinib in Combination With KEYTRUDA®
Nov 06, 2019
BerGenbio's Bemcentinib Meets Primary Endpoint in First Cohort of Phase 2 NSCLC Study in Combination With Keytruda®
Oct 22, 2019
BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
Oct 02, 2019
BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting
Sep 28, 2019
Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019
Sep 27, 2019
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress
Aug 19, 2019
BerGenBio ASA: Results for the Second Quarter and First Half 2019
Jun 14, 2019
BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy
Jun 12, 2019
Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia andSmall Lymphocytic Lymphoma
Jun 02, 2019
BerGenBio Presents New Preliminary Clinical and Biomarker Data Showing Durable Response & Median Survival Rates in Phase II Trial With Bemcentinib and KEYTRUDA in Pts With Advanced NSCLC at ASCO 2019
May 15, 2019
BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019
May 08, 2019
BerGenBio Completes Recruitment Into Second Stage of Phase II Trial With Selective AXL inhibitor bemcentinib in Combination with KEYTRUDA® in Patients With Advanced NSCLC